Adriana Ros, DO
Dermatology · Clifton, NJNPI 1942468392
Payments from drug & device makers
Across 849 payments — averaging $156.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$59K
- AbbVie$41K
- Kowa Pharmaceuticals America, Inc.$13K
- Pfizer$6K
- Journey Medical Corporation$3K
- EPI Health, LLC$2K
- plus $11K from 42 others
What the payments were for
- Consulting fees$41,68631%
- Speaking & faculty fees$62,70447%
- Travel & lodging$12,84410%
- Food & beverage$14,97911%
- Education$5600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZORYVE$49,950
- Humira$22,701
- Skyrizi$10,850
- EUCRISA$5,250
- Rinvoq$2,386
- Sitavig$1,250
- Cloderm$1,250
- Minolira 105mg$1,250
- Minolira 135mg$1,250
- Rhofade$1,250
- QBREXZA$1,249
- Accutane$1,000
- Promiseb Complete$500
- Sernivo$500
- TRIANEX 0.05%$500
- Genadur$500
- Ketodan$500
- Tovet (emollient formulation)$500
- Neo-Synalar$350
- Clindacin ETZ$350
How this compares
$132,773 in reported general payments places this provider in the 95th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $296,579 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 29 | $243,535 |
| Humira(Cf) PenAdalimumab | 21 | $139,921 |
| Taltz AutoinjectorIxekizumab | 17 | $113,799 |
| OtezlaApremilast | 15 | $86,772 |
| Dupixent PenDupilumab | 18 | $69,028 |
| OpzeluraRuxolitinib Phosphate | 11 | $22,208 |
| Clobetasol Propionate | 124 | $7,838 |
| Calcipotriene | 35 | $6,612 |
| Tacrolimus | 63 | $6,097 |
| Ketoconazole | 261 | $4,363 |
| Betamethasone Dipropionate | 23 | $2,762 |
| Fluorouracil | 32 | $2,251 |
| Ammonium Lactate | 66 | $1,832 |
| Azelaic Acid | 19 | $1,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $193 | $86,77215 claims |
| Incyte CorporationOpzelura | $568 | $22,20811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 394 dermatology providers in New Jersey.
Other dermatology in Clifton
- Jerry BagelEast Windsor$15.4M
- Jonathan DosikGlen Rock$8.4M
- Omar NoorSomerset$4.6M
- Linda Cappiello-LindsleyHoboken$2.3M
- Winston MoyDenville$1.8M
- Brian KeeganEast Windsor$1.7M
- Jeanine DownieMontclair$1.2M
- Adolfo Fernandez ObregonHoboken$1.1M
- Mital Patel CohenFlorham Park$799K
- Ronald BernardinVoorhees$688K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.